Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

Author(s):
Younes, A.; Thieblemont, C.; Morschhauser, F.; Flinn, I.; Friedberg, J.W.; Amorim, S.; Hivert, B.; Westin, J.; Vermeulen, J.; Bandyopadhyay, N.; Vries, R. de; Balasubramanian, S.; Hellemans, P.; Smit, J.W.; Fourneau, N.; Oki, Y.
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-08-31
Language
English
Is part of
The Lancet Oncology (2014), Vol. 15, no. 9, p. 1019-1026
hdl
1887/103182
doi
10.1016/S1470-2045(14)70311-0